跳转至内容
Merck
CN

SML2261

Conivaptan hydrochloride

≥98% (HPLC)

别名:

N-[4-[(4,5-dihydro-2­methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]- [1,1’-biphenyl]-2-carboxamide monohydrochloride

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C32H26N4O2 · HCl
化学文摘社编号:
分子量:
535.04
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

Conivaptan hydrochloride, ≥98% (HPLC)

InChI

1S/C32H26N4O2.ClH/c1-21-33-28-19-20-36(29-14-8-7-13-27(29)30(28)34-21)32(38)23-15-17-24(18-16-23)35-31(37)26-12-6-5-11-25(26)22-9-3-2-4-10-22;/h2-18H,19-20H2,1H3,(H,33,34)(H,35,37);1H

SMILES string

O=C(NC1=CC=C(C(N2CCC(N=C(C)N3)=C3C4=C2C=CC=C4)=O)C=C1)C5=CC=CC=C5C6=CC=CC=C6.Cl

InChI key

BTYHAFSDANBVMJ-UHFFFAOYSA-N

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

Biochem/physiol Actions

Conivaptan hydrochloride is a novel dual Arginine vasopressin receptor (AVP-R) antagonist for AVP-R types 1a (V1a) and V2-R. Conivaptan potently inhibits AVP-induced intracellular signaling through human V2 and V1a receptors with no agonistic activity.
Nonpeptide, dual vasopressin V1a/V2 receptor antagonist

pictograms

Health hazard

signalword

Warning

hcodes

Hazard Classifications

Repr. 2

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

监管及禁止进口产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Poornima Vinod et al.
Cardiology research, 8(3), 87-95 (2017-07-21)
Heart and kidney failure continued to be of increasing prevalence in today's society, and their comorbidity has synergistic effect on the morbidity and mortality of patients. Cardiorenal syndrome (CRS) is a complex disease with multifactorial pathophysiology. Better understanding of this
A Tahara et al.
The Journal of pharmacology and experimental therapeutics, 282(1), 301-308 (1997-07-01)
The biochemical and pharmacological profile of YM087, 4'-[(2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepin- 6-yl)-carbonyl]-2-phenylbenzanilide monohydrochloride, a newly synthesized nonpeptide vasopressin (AVP) antagonist, was investigated in several in vitro and in vivo studies. YM087 showed high affinity for V1A receptors from rat liver and V2 receptors
Yukinori Arai et al.
Journal of pharmacological sciences, 109(1), 53-59 (2009-01-20)
Hyponatremia is the most common electrolyte disorder in hospitalized patients and is associated with the risk of intractable seizures and death. The effectiveness of conventional therapies for hyponatremia is inconsistent, and the rapid correction of plasma sodium levels is thought

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持